TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32200714

Group type: EXPERIMENTAL
Intervention: PAD subjects
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-PAD subjects
Number of subjects: 33
Study: 32200718

Group type: EXPERIMENTAL
Intervention: Dietary Patterns (DPs) identified as 'alcohol', 'fast food and alcohol', 'fried, processed, and dairy products', 'meat, starch, sodas, and fat' in G1 and G2 men and women.
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: 'Alcohol' DP in G1 men.
Number of subjects: 1527
Study: 32200854

Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter 2 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32201256

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (support vector machines, random forests, gradient boosting machines, artificial neural networks)
Number of subjects: 11022

Group type: COMPARATOR
Intervention: Logistic regression, lasso regression, ridge regression
Number of subjects: 11022
Study: 32201274

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment
Number of subjects: 2648
Study: 32201506

Group type: EXPERIMENTAL
Intervention: Sorafenib (200 mg orally twice daily, days 1-5 and 8-12) and Bevacizumab (5 mg/kg intravenously, day 1) every 2 weeks
Number of subjects: 79
Study: 32201505

Group type: EXPERIMENTAL
Intervention: PF-06649751
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 32202224

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 20
Study: 32202706

Group type: EXPERIMENTAL
Intervention: Total daily sitting
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Occupational sitting
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Television viewing
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Computer use
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Daily sedentary time (accelerometer subsample)
Number of subjects: 380
Study: 32203069

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg daily for 4-12 weeks
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg daily for >50 days
Number of subjects: 33
Study: 32203155

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 2586
Study: 32203233

Group type: EXPERIMENTAL
Intervention: 3-dimensional optical imaging (3DO)
Number of subjects: 179

Group type: COMPARATOR
Intervention: 4-component (4C) model
Number of subjects: 179
Study: 32203268

Group type: EXPERIMENTAL
Intervention: Treosulfan-based conditioning treatment
Number of subjects: 65
Study: 32203306

Group type: EXPERIMENTAL
Intervention: Plasma circulating tumour DNA (ctDNA) analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma ctDNA testing
Number of subjects: 0
Study: 32203698

Group type: EXPERIMENTAL
Intervention: Pemigatinib 13.5 mg orally once daily (21-day cycle; 2 weeks on, 1 week off)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 146
Study: 32204733

Group type: EXPERIMENTAL
Intervention: melphalan hypoxic pelvic perfusion (HPP)
Number of subjects: 7
Study: 32205016

Group type: EXPERIMENTAL
Intervention: Capivasertib (AZD5363) 320 mg, 400 mg, and 480 mg twice daily (b.i.d.) for 4 days on and 3 days off in combination with enzalutamide 160 mg daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Capivasertib (AZD5363) 400 mg b.i.d. with enzalutamide 160 mg daily
Number of subjects: 16
Study: 32205017

Group type: EXPERIMENTAL
Intervention: Ipatasertib 600 mg combined with paclitaxel
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Ipatasertib 600 mg combined with mFOLFOX6
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Ipatasertib 400 mg combined with paclitaxel
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Ipatasertib combined with docetaxel
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Ipatasertib combined with enzalutamide
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Ipatasertib combined with chemotherapy or hormonal therapy
Number of subjects: 122
Study: 32205068

Group type: EXPERIMENTAL
Intervention: Nonfasting
Number of subjects: 15397
Study: 32205112

Group type: EXPERIMENTAL
Intervention: TEVAR with JOTEC E-XL open stent
Number of subjects: 39

Group type: COMPARATOR
Intervention: TEVAR alone
Number of subjects: 39
Study: 32205128

Group type: EXPERIMENTAL
Intervention: Endovenous laser therapy using a 400-μm optical fiber with a 1470-nm laser
Number of subjects: 0
Study: 32205218

Group type: EXPERIMENTAL
Intervention: CT-based deep convolutional neural network (CNN) analysis
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: MR-based deep convolutional neural network (CNN) analysis
Number of subjects: 950
Study: 32205328

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor therapy
Number of subjects: 20
Study: 32205604

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 1017
Study: 32205788

Group type: EXPERIMENTAL
Intervention: Common Data Elements (CDEs) applied across studies
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Standardized codebooks and data collection protocols
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Research data repository for self-management of chronic conditions
Number of subjects: 179
Study: 32206091

Group type: EXPERIMENTAL
Intervention: Posterior circulation ICAPs
Number of subjects: 202

Group type: COMPARATOR
Intervention: Anterior circulation ICAPs
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Diffuse distribution ICAP feature
Number of subjects: 202
Study: 32206312

Group type: EXPERIMENTAL
Intervention: Culturally competent social robots
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 32206334

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) + usual care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 50
Study: 32206659

Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of bupivacaine
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Pulmonary recruitment maneuver with intraperitoneal bupivacaine
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Combination of pulmonary recruitment maneuver and intraperitoneal bupivacaine
Number of subjects: 287
Study: 32206660

Group type: EXPERIMENTAL
Intervention: Oxaloacetate/vitamin C (2 capsules of 100 mg oxaloacetate/150 mg ascorbic acid)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (2 capsules of rice flour)
Number of subjects: 48
Study: 32206673

Group type: EXPERIMENTAL
Intervention: Early Functional Mobilization (EFM) including immediate postoperative loading and ankle motion
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard treatment (2 weeks of unloading in a plaster cast followed by 4 weeks of weightbearing in an orthosis)
Number of subjects: 135
Study: 32206779

Group type: EXPERIMENTAL
Intervention: mTOR inhibition with sirolimus
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: IL-6 stimulation
Number of subjects: 88

Group type: COMPARATOR
Intervention: mTORC1 signaling
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Baseline mTOR pathway activation
Number of subjects: 88
Study: 32206973

Group type: EXPERIMENTAL
Intervention: Adalimumab therapy for 24 months
Number of subjects: 783
Study: 32206976

Group type: EXPERIMENTAL
Intervention: Concurrent scalp-sparing radiation (60 Gy in 30 fractions) with standard concurrent temozolomide (75 mg/m2) and tumor treatment fields (TTFields)
Number of subjects: 10
Study: 32206991

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 13
Study: 32207049

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 23
Study: 32207164

Group type: EXPERIMENTAL
Intervention: Imalumab (oxMIF inhibitor) at doses of 1 to 50 mg/kg IV every 2 weeks or 10 or 25 mg/kg IV weekly (1 cycle = 28 days)
Number of subjects: 50
Study: 32208121

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM) performed at baseline in all patients.
Number of subjects: 1027

Group type: EXPERIMENTAL
Intervention: Therapeutic adjustment or treatment switch after pathological ABPM.
Number of subjects: 1027

Group type: EXPERIMENTAL
Intervention: Initiation of antihypertensive therapy after pathological ABPM.
Number of subjects: 1027
Study: 32208831

Group type: EXPERIMENTAL
Intervention: Cryptogenic ischemic stroke patients
Number of subjects: 60
Study: 32208873

Group type: EXPERIMENTAL
Intervention: Molecularly matched therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32208953

Group type: EXPERIMENTAL
Intervention: Clinical assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphofluoroscopy
Number of subjects: 0
Study: 32208957

Group type: EXPERIMENTAL
Intervention: Ivosidenib (AG-120) monotherapy
Number of subjects: 21
Study: 32209572

Group type: EXPERIMENTAL
Intervention: Ibrutinib (single-agent)
Number of subjects: 0
Study: 32209584

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 19
Study: 32209624

Group type: EXPERIMENTAL
Intervention: Current systemic or topical treatment for AD (at the discretion of the investigator)
Number of subjects: 1300
Study: 32209628

Group type: EXPERIMENTAL
Intervention: Elective sigmoidectomy
Number of subjects: 0
Study: 32209661

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32210181

Group type: EXPERIMENTAL
Intervention: Severe OSA (AHI > 30 events/h)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Moderate OSA (AHI > 10)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Matched controls (AHI < 5)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Controls (AHI < 5)
Number of subjects: 128
Study: 32210458

Group type: EXPERIMENTAL
Intervention: TDF-containing regimen
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-TDF-containing regimen
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Pre-treatment CD4+ count <350 cells/mm3
Number of subjects: 106
Study: 32210527

Group type: EXPERIMENTAL
Intervention: 2 mg intravitreal aflibercept (IVT-AFL) every 4 weeks (2q4)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 2 mg intravitreal aflibercept (IVT-AFL) every 8 weeks (2q8)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Macular laser photocoagulation (laser control group)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 2 mg intravitreal aflibercept (IVT-AFL)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 378
Study: 32210548

Group type: EXPERIMENTAL
Intervention: VWF-N
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: VWF-A
Number of subjects: 984
Study: 32210639

Group type: EXPERIMENTAL
Intervention: Flexible extended regimen of ethinylestradiol/drospirenone (EE/DRSP)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Cyclic regimen of ethinylestradiol/drospirenone (EE/DRSP)
Number of subjects: 212
Study: 32210897

Group type: EXPERIMENTAL
Intervention: Weight self-monitoring (Intervention Group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No weight self-monitoring (Control Group)
Number of subjects: 54
Study: 32210906

Group type: EXPERIMENTAL
Intervention: Nilvadipine (dihydropyridine calcium channel blocker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32211336

Group type: EXPERIMENTAL
Intervention: Lithium carbonate 300 mg given 2-3 times daily, adjusted to target serum concentration (0.6 to 1.0 mmol/L); Tretinoin 22.5 or 45 mg/m²
Number of subjects: 9
Study: 32211554

Group type: EXPERIMENTAL
Intervention: SCHOOL IN ACTION program
Number of subjects: 0
Study: 32211756

Group type: EXPERIMENTAL
Intervention: 3 g of ceftolozane/tazobactam administered q8h
Number of subjects: 26
Study: 32212002

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fetuin-A and TBG levels
Number of subjects: 0
Study: 32212061

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor and Clopidogrel
Number of subjects: 0
Study: 32212069

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 83

Group type: COMPARATOR
Intervention: Food insecurity (FI)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Health-related quality of life (HRQoL)
Number of subjects: 83
Study: 32212104

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%, applied twice daily for 28 days
Number of subjects: 137
Study: 32212368

Group type: EXPERIMENTAL
Intervention: A1C ≥ 8% and LVEF < 40%
Number of subjects: 4091

Group type: COMPARATOR
Intervention: A1C < 7% and LVEF ≥ 50%
Number of subjects: 4091

Group type: EXPERIMENTAL
Intervention: Per 1% higher A1C
Number of subjects: 4091

Group type: EXPERIMENTAL
Intervention: Per 10% lower in LVEF
Number of subjects: 4091
Study: 32212910

Group type: EXPERIMENTAL
Intervention: Higher exercise capacity (measured in METs)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Self-reported exercise
Number of subjects: 270
Study: 32212933

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance vector analysis-derived phase angle
Number of subjects: 0
Study: 32212944

Group type: EXPERIMENTAL
Intervention: octanorm (cutaquig)
Number of subjects: 0
Study: 32213027

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard biopsies
Number of subjects: 67
Study: 32213183

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) increase of 1 SD in men
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) increase of 1 SD in women
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Fourth quartile of WC in men
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Fourth quartile of WC in women
Number of subjects: 10251
Study: 32213338

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-LC29 questionnaire
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 questionnaire
Number of subjects: 523
Study: 32213344

Group type: EXPERIMENTAL
Intervention: Melflufen plus dexamethasone (40 mg melflufen, 40 mg dexamethasone weekly)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Single-agent melflufen
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Melflufen plus dexamethasone
Number of subjects: 81
Study: 32213479

Group type: EXPERIMENTAL
Intervention: mHealth devices (AnaMed Original Equipment Manufacturer device and Air Next mobile spirometry device) used for 90 days alongside standard care
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: mHealth devices
Number of subjects: 27
Study: 32213649

Group type: EXPERIMENTAL
Intervention: setmelanotide
Number of subjects: 1

Group type: COMPARATOR
Intervention: metreleptin
Number of subjects: 1
Study: 32213860

Group type: EXPERIMENTAL
Intervention: Self-Care for Older PErsons (SCOPE) program
Number of subjects: 378
Study: 32214793

Group type: EXPERIMENTAL
Intervention: 0.19 mg Fluocinolone Acetonide intravitreal implant
Number of subjects: 22
Study: 32215273

Group type: EXPERIMENTAL
Intervention: Gentle Jogger (JD) used for 30 minutes, 3 times per day for 7 days
Number of subjects: 22
Study: 32215826

Group type: EXPERIMENTAL
Intervention: Controlled ovarian stimulation (COS) with gonadotropins
Number of subjects: 2901
Study: 32216697

Group type: EXPERIMENTAL
Intervention: Laparoscopic Keyhole Repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sugarbaker Repair
Number of subjects: 0
Study: 32216750

Group type: EXPERIMENTAL
Intervention: Mouth culture
Number of subjects: 200

Group type: COMPARATOR
Intervention: Throat culture (reference standard)
Number of subjects: 200
Study: 32216919

Group type: EXPERIMENTAL
Intervention: Baseline Anemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no baseline anemia)
Number of subjects: 0
Study: 32216975

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 2130
Study: 32217004

Group type: EXPERIMENTAL
Intervention: Supported self-management (SMS) program
Number of subjects: 15
Study: 32217063

Group type: EXPERIMENTAL
Intervention: Isolated PE
Number of subjects: 510
Study: 32217226

Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD)
Number of subjects: 739
Study: 32217652

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32217877

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs) including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the Outcomes and Experiences Questionnaire
Number of subjects: 0
Study: 32218061

Group type: EXPERIMENTAL
Intervention: Vertical Jump (VJ) on a force plate
Number of subjects: 20
Study: 32218346

Group type: EXPERIMENTAL
Intervention: Resectable group (Res)
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Locally advanced group (LA)
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Metastatic group (Met)
Number of subjects: 814
Study: 32218581

Group type: EXPERIMENTAL
Intervention: pOpmètre® device
Number of subjects: 50

Group type: COMPARATOR
Intervention: SphygmoCor® device
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: pOpmètre® device with algorithm correction
Number of subjects: 50
Study: 32218749

Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 60

Group type: COMPARATOR
Intervention: sham iTBS
Number of subjects: 60
Study: 32218807

Group type: EXPERIMENTAL
Intervention: Apatinib (first line, second line, and third or higher line therapy)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Apatinib (low-dose 250 mg, mid-dose 425-500 mg, high-dose 675-850 mg)
Number of subjects: 337
Study: 32219330

Group type: EXPERIMENTAL
Intervention: Metformin treatment (MET)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Nonpharmacological treatment (NPT)
Number of subjects: 249
Study: 32219388

Group type: EXPERIMENTAL
Intervention: Phased radiofrequency ablation
Number of subjects: 1054
Study: 32219418

Group type: EXPERIMENTAL
Intervention: Composite risk score
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Self-served food portions
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Eating rate
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Lunch intakes
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Eating behaviors moderation
Number of subjects: 302
Study: 32219421

Group type: EXPERIMENTAL
Intervention: Maternal fasting glucose increase (1-mmol/L)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Maternal 2-h OGTT glucose increase (1-mmol/L)
Number of subjects: 305
Study: 32219431

Group type: EXPERIMENTAL
Intervention: Hydrocodone-acetaminophen prescribed (median 12 pills)
Number of subjects: 260
Study: 32219675

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 264
Study: 32220010

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement/repair (MVR)
Number of subjects: 42
Study: 32220591

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced magnetic resonance lymphangiography (DCMRL)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DCMRL
Number of subjects: 16
Study: 32220908

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle until disease progression, death, or unacceptable toxicity.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Regorafenib-related TEAEs
Number of subjects: 100
Study: 32220910

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 24218
Study: 32221013

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Haploidentical NK cell infusion
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: NK cells
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Endogenously reconstituted NK cells
Number of subjects: 63
Study: 32221099

Group type: EXPERIMENTAL
Intervention: Preoxygenation with 100% O2 for 3 minutes in adults
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Administration of opioids during RSI in adults
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Use of the Sellick manoeuvre in adults
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: First-line medications for haemodynamically stable adults: propofol
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: First-line medications for haemodynamically stable adults: suxamethonium
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Manual ventilation (inspiratory pressure <12 cmH2O) in adults
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Preoxygenation with 100% O2 for 3 minutes in paediatric patients
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Administration of opioids during RSI in paediatric patients
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Use of the Sellick manoeuvre in paediatric patients
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Manual ventilation (inspiratory pressure <12 cmH2O) in paediatric patients
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: First-line medications for haemodynamically stable children: propofol
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: First-line medications for haemodynamically stable children: rocuronium
Number of subjects: 1921
Study: 32221675

Group type: EXPERIMENTAL
Intervention: NAC-treated graft (NAC-enriched tumescent fluid)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control graft (standard tumescent fluid)
Number of subjects: 15
Study: 32221866

Group type: EXPERIMENTAL
Intervention: Capsaicin 0.075% + Diclofenac 2%
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Capsaicin 0.075%
Number of subjects: 746

Group type: COMPARATOR
Intervention: Diclofenac 2%
Number of subjects: 746

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 746
Study: 32222808

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (pola) 1.0-1.8 mg/kg administered intravenously every 3 weeks (q3w) with R/G-CHP
Number of subjects: 0
Study: 32222841

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32223334

Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Number of subjects: 0
Study: 32223740

Group type: EXPERIMENTAL
Intervention: mNavigator digital health application for protocol compliance in pediatric cancer treatment
Number of subjects: 0
Study: 32223937

Group type: EXPERIMENTAL
Intervention: Larotrectinib (oral TRK inhibitor)
Number of subjects: 1